|The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins.|
|Jump to Full Text|
|PMID: 21852397 Owner: NLM Status: MEDLINE|
|Neuropilin 1 (NRP1) is a transmembrane glycoprotein that is essential for blood vessel development in vertebrates. Best known for its ability to bind members of the vascular endothelial growth factor (VEGF) and class 3 semaphorin families through its extracellular domain, it also has a highly conserved cytoplasmic domain, which terminates in a SEA motif that binds the PDZ protein synectin/GIPC1/NIP. Previous studies in zebrafish embryos and tissue culture models raised the possibility that the SEA motif of NRP1 is essential for angiogenesis. Here, we describe the generation of mice that express a form of NRP1 that lacks the cytoplasmic domain and, therefore, the SEA motif (Nrp1(cyto)(Δ)(/)(Δ) mice). Our analysis of pre- and perinatal vascular development revealed that vasculogenesis and angiogenesis proceed normally in these mutants, demonstrating that the membrane-anchored extracellular domain is sufficient for vessel growth. By contrast, the NRP1 cytoplasmic domain is required for normal arteriovenous patterning, because arteries and veins crossed each other at an abnormally high frequency in the Nrp1(cyto)(Δ)(/)(Δ) retina, as previously reported for mice with haploinsufficient expression of VEGF in neural progenitors. At crossing sites, the artery was positioned anteriorly to the vein, and both vessels were embedded in a shared collagen sleeve. In human eyes, similar arteriovenous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which compression of the vein by the artery disrupts retinal blood flow, causing local tissue hypoxia and impairing vision. Nrp1(cyto)(Δ)(/)(Δ) mice may therefore provide a suitable genetic model to study the aetiology of BRVO.|
|Alessandro Fantin; Quenten Schwarz; Kathryn Davidson; Eduardo M Normando; Laura Denti; Christiana Ruhrberg|
Related Documents :
|10208107 - Diagnosis of mca-occlusion and monitoring of systemic thrombolytic therapy with contras...
16376197 - Assessment of short-term outcomes for protected carotid angioplasty with stents using r...
14959917 - The preoperative cerebrovascular consultation: common cerebrovascular questions before ...
16060177 - Management of carotid artery stenosis. update for family physicians.
19632437 - Combined off-pump coronary artery bypass grafting and thyroidectomy.
11435637 - Predictors of re-occlusion after successful recanalization of chronic total occlusion.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-08-18|
|Title: Development (Cambridge, England) Volume: 138 ISSN: 1477-9129 ISO Abbreviation: Development Publication Date: 2011 Oct|
|Created Date: 2011-09-07 Completed Date: 2011-11-22 Revised Date: 2013-06-28|
Medline Journal Info:
|Nlm Unique ID: 8701744 Medline TA: Development Country: England|
|Languages: eng Pagination: 4185-91 Citation Subset: IM|
|UCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.|
|APA/MLA Format Download EndNote Download BibTex|
Amino Acid Motifs
Collagen / metabolism
Cytoplasm / metabolism
Gene Expression Regulation, Developmental*
Molecular Sequence Data
Neuropilin-1 / metabolism*
Retinal Artery / embryology, pathology*
Retinal Vein / embryology, pathology*
Sequence Homology, Amino Acid
Sequence Homology, Nucleic Acid
Vascular Endothelial Growth Factor A / metabolism
|44626//British Heart Foundation; G0601093//Medical Research Council; PG/10/86/28622//British Heart Foundation|
|0/Vascular Endothelial Growth Factor A; 144713-63-3/Neuropilin-1; 9007-34-5/Collagen|
Journal ID (nlm-ta): Development
Journal ID (hwp): develop
Journal ID (publisher-id): dev
Publisher: Company of Biologists
Accepted Day: 21 Month: 7 Year: 2011
Print publication date: Day: 1 Month: 10 Year: 2011
pmc-release publication date: Day: 1 Month: 10 Year: 2011
Volume: 138 Issue: 19
First Page: 4185 Last Page: 4191
PubMed Id: 21852397
|The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins|
|Eduardo M. Normando|
|UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.
|‡ Author for correspondence (firstname.lastname@example.org)
*These authors contributed equally to this work
†Present address: Department of Human Immunology, Centre for Cancer Biology, Frome Road, Adelaide, 5000 South Australia
Organ development, homeostasis and repair rely on properly perfused blood vessel networks, which form during embryogenesis and postnatal development (Risau, 1997). The first blood vessels in the embryo are assembled from single cell precursors in a process known as vasculogenesis. This primitive plexus expands by sprouting angiogenesis and is remodelled into a hierarchical vascular tree containing capillaries, arterioles, venules, arteries and veins. A key molecule promoting all stages of vascular development is the vascular endothelial growth factor VEGF, which exists in four isoforms known as VEGF120, VEGF144, VEGF164 and VEGF188 in mice, and VEGF121, VEGF145, VEGF165 and VEGF189 in humans (Ruhrberg, 2003). All VEGF isoforms bind the receptor tyrosine kinases VEGFR1 (FLT1) and VEGFR2 (KDR, FLK1). VEGFR2 is the main signalling VEGF receptor in endothelial cells, but its activity is balanced by VEGFR1, which sequesters excess VEGF with its extracellular domain (Shibuya, 2006; Kappas et al., 2008).
The neuropilins NRP1 and NRP2 are non-tyrosine kinase receptors for VEGF. NRP1 preferentially binds VEGF165, whereas NRP2 binds both VEGF165 and VEGF145 (Soker et al., 1998; Gluzman-Poltorak et al., 2000). A recent study suggests that VEGF121 also binds NRP1 in human endothelial cells that express KDR (Pan et al., 2007). NRP1-deficient mice die between embryonic day (E) 10.5 and 14.5 with defects in brain, spinal cord and yolk sac vasculature, and disrupted aortic arch remodelling (Kawasaki et al., 1999; Gerhardt et al., 2004; Schwarz et al., 2004; Jones et al., 2008), whereas NRP2-deficient mice survive postnatally with lymphatic, but not blood vascular defects (Yuan et al., 2002).
NRP1 has a large extracellular domain of 860 amino acid residues, a short transmembrane domain of 23 amino acids and an intracellular domain of 39 amino acids (Fujisawa, 2002; Schwarz and Ruhrberg, 2010). In neurons, NRP1 recruits plexins to transduce semaphorin signals independently of the NRP1 cytoplasmic tail (Nakamura et al., 1998). By analogy, it has been proposed that NRP1 recruits VEGFR1 or VEGFR2 to transduce VEGF signals in endothelial cells (e.g. Soker et al., 1998; Gluzman-Poltorak et al., 2001; Fantin et al., 2009). In agreement, NRP1 enhances VEGFR2 signalling by binding VEGF165 and promotes complex formation between the three molecules in cultured endothelial cells (Soker et al., 1998; Whitaker et al., 2001; Soker et al., 2002). VEGFR2/NRP1 interaction also requires the three C-terminal amino acids (SEA) of the NRP1 cytoplasmic domain, which confer binding to the PDZ protein synectin, also known as NIP or GIPC1 (De Vries et al., 1998; Cai and Reed, 1999; Gao et al., 2000; Prahst et al., 2008). The SEA motif promotes VEGF-dependent endothelial migration and fibronectin assembly in vitro (Wang et al., 2006; Valdembri et al., 2009).
Morpholino-induced Nrp1 knockdown in zebrafish impairs intersomitic vessel (ISV) growth, which is rescued by the forced expression of full-length, but not SEA-deficient NRP1 (Wang et al., 2006). Synectin knockdown in zebrafish also inhibits ISV sprouting and additionally impairs dorsal aorta formation (Chittenden et al., 2006). In mice, however, synectin is not required for developmental angiogenesis, but instead promotes mural cell recruitment to retinal blood vessels by regulating PDGF signalling (Paye et al., 2009) and arterial branching in pathological tissue ischemia by enhancing VEGFR2 signalling (Chittenden et al., 2006; Lanahan et al., 2010). By contrast, it has not previously been determined whether the NRP1 cytoplasmic domain is essential for vascular development in mice.
Here, we describe the generation of mice that express a form of NRP1 that lacks the cytoplasmic domain (Nrp1cytoΔ/Δ). Nrp1cytoΔ/Δ mutants undergo normal vasculogenesis and angiogenesis, demonstrating that membrane-anchored extracellular NRP1 is sufficient for both processes. However, retinal arteries and veins crossed each other at an abnormally high frequency, as previously reported for mice with haploinsufficient expression of neural progenitor-derived VEGF (Haigh et al., 2003). The phenotypic similarity of mutants with reduced VEGF levels and mutants lacking the NRP1 cytoplasmic domain suggests that NRP1 signalling conveys VEGF signals to implement the spatial separation of arteries and veins. We further show that arteriovenous crossings in Nrp1cytoΔ/Δ mice are similar to those at sites of branch retinal vein occlusion (BRVO), a human eye pathology in which blockage of blood flow in a branch of the central retinal vein causes loss of vision.
A targeting construct introducing a stop codon and a neomycin cassette into Nrp1 after the transmembrane domain was inserted into BACPAC clone RP23-298G15 (Children's Hospital Oakland Research Institute, California) by ET recombineering (Angrand et al., 1999). Homologously recombined embryonic stem (ES) cell clones were identified by Southern blotting and aggregated with CD1 mouse embryos. A germline-transmitting male was mated to a female HprtCre carrier to delete the neomycin cassette. Offspring was backcrossed into C57/Bl6 (Charles River Laboratories) and genotyped by PCR with the oligonucleotides 5′-CCTTTTGATGGACATGTGACCTGTAGC-3′ (Nrp1-F), 5′-CACCAGGTCTGATTGAAGAGAAGG-3′ (Nrp1-R) and 5′-ATGGTACCTTGAGCATCTGACTTCTG-3′ (Nrp1-ΔC). Protein lysates from primary cardiac endothelial cells (Allport et al., 2002) were immunoblotted with rabbit anti-mouse (Cell Signalling) and anti-human NRP1 (Epitomics), followed by goat anti-rabbit horseradish peroxidase-coupled secondary antibodies (DAKO). Immunostaining, imaging and quantitations were performed as described previously (Vieira et al., 2007; Fantin et al., 2010), but including anti-NG2 (Millipore). Confocal z-stacks of arteriovenous crossings, obtained with the LSM710 microscope (Zeiss), were subjected to three-dimensional surface rendering with Imaris (Bitplane). Animal research was conducted with United Kingdom Home Office and local ethical approval.
We introduced a stop codon into the last exon of mouse Nrp1, immediately downstream of the transmembrane domain (Fig. 1A). Southern blotting identified targeted ES cells (Fig. 1B) and confirmed gene targeting in mice derived from these cells (Fig. 1C). PCR genotyping (Fig. 1D) established that wild type, heterozygotes (Nrp1+/cytoΔ) and homozygotes (Nrp1cytoΔ/Δ) were present at the expected Mendelian ratio (see Table S1 in the supplementary material). Mutant mice were viable, fertile and appeared anatomically normal. Sequencing reverse-transcribed cDNA from mutants and wild-type littermates with oligonucleotide primers for Nrp1 confirmed that a 4 bp insertion in the mutants introduced a premature stop codon at the end of the transmembrane domain and shifted the mRNA reading sequence out of frame, which prevented translation of the cytoplasmic domain (Fig. 1F). Immunoblotting of proteins from primary cardiac endothelial cells also confirmed deletion of the cytoplasmic domain in the mutants. Thus, an antibody for the NRP1 cytoplasmic domain (αC) detected a doublet of 130-135 kDa in wild types, as expected (e.g. Soker et al., 1998; Gu et al., 2002), but failed to bind NRP1 in mutants (Fig. 1G). By contrast, an antibody for the extracellular domain (αN) detected NRP1 in wild types and mutants (Fig. 1G). Mutant NRP1 migrated at a lower molecular weight, as predicted by the C-terminal 40 amino acid deletion (Fig. 1F,G). The cDNA and protein analyses established that the cytoplasmic domain was successfully deleted in Nrp1cytoΔ/Δ mice and that mutant NRP1 protein was stably expressed.
We compared vascular development in E9.5 Nrp1cytoΔ/Δ and wild-type littermates by immunofluorescence (Fig. 2A-F). The dorsal aorta and pharyngeal arch arteries, formed by vasculogenesis, and microvessel networks, which arise through angiogenesis, appeared normal in mutants (Fig. 2A,D). Higher magnification images also showed normal remodelling of head vessels (Fig. 2B,E) and appropriate branching of intersomitic and other trunk vessels in mutants (Fig. 2C,F). Double immunostaining of mutants and wild types with the NRP1 extracellular domain antibody demonstrated similar NRP1 localisation to blood vessels (Fig. 2B′,C′,E′,F′) and the trigeminal ganglia (arrowheads in Fig. 2B′,E′), known to express NRP1 at this developmental stage (Schwarz et al., 2008). The lack of obvious vascular or other morphological defects at E9.5 suggests that the requirement for NRP1/synectin signalling in fish (Wang et al., 2006) is not conserved in mammals.
NRP1-deficiency disrupts angiogenesis in the central nervous system, including the hindbrain (Gerhardt et al., 2004; Kawasaki et al., 1999). Thus, vessels invading the brain from the pial surface normally fuse into the subventricular vascular plexus (SVP) that supplies the neural progenitors by E12.5 (Fig. 2G) (Ruhrberg et al., 2002), but Nrp1-null mutants lack the SVP (Fig. 2I). In Nrp1cytoΔ/Δ mutants, the SVP formed (Fig. 2H) and contained a normal number of branchpoints (Fig. 2J; wild type 55.39±4.74 versus Nrp1cytoΔ/Δ 57.29±4.40; mean±s.d.; n≥4 each). Together with the E9.5 analysis, these findings show that membrane-anchored NRP1 is sufficient for vasculogenesis and angiogenesis.
To determine whether the NRP1 cytoplasmic domain regulates postnatal vascular development, we compared retinal angiogenesis in Nrp1cytoΔ/Δ and their wild-type littermates on perinatal day (P) 7, when vessels extend from the centre to the periphery, and at P21, when angiogenesis is largely complete in this organ (Fruttiger, 2007). In both genotypes, vessels had extended similarly towards the periphery at P7 (Fig. 3A-C) and into the deeper retinal layers to form three plexi at P21 (see Fig. S1A-F in the supplementary material). Endothelial cell growth and migration in the retina therefore proceeds normally in mice lacking the NRP1 cytoplasmic domain, as reported for mice deficient in synectin (Paye et al., 2009).
Synectin knockout mice show defective mural cell recruitment to retinal vessels (Paye et al., 2009). By contrast, staining of Nrp1cytoΔ/Δ mutants for α-smooth muscle actin (SMA) showed normal smooth muscle cell (SMC) coverage of arteries at P7 (Fig. 3A′,B′,D) and P21 (Fig. 3G,H). Staining for the pericyte marker NG2 (Ozerdem et al., 2001) also showed a normal distribution of mural cells along arteries, veins and capillaries in mutants (see Fig. S2 in the supplementary material). Nrp1cytoΔ/Δ mice therefore do not phenocopy synectin knockouts with respect to mural cell recruitment, consistent with the idea that reduced PDGF, rather than VEGF signalling, is responsible for mural cell defects in synectin knockouts (Paye et al., 2009).
Because NRP1 is more highly expressed in developing arteries than veins, we next examined arteriovenous patterning in the Nrp1cytoΔ/Δ retina. In the mutant retina, arteries and veins radiated from the optic nerve head in the centre towards the periphery in their usual alternating pattern (Fig. 3A,B), and arteries and veins were present at a normal number (Fig. 3I; arteries: Nrp1+/+ 5.38±0.92 versus Nrp1cytoΔ/Δ 5.58±0.79; veins: Nrp1+/+ 5.38±1.3 versus Nrp1cytoΔ/Δ 5.58±1.08; mean±s.d., n≥8 each). Unexpectedly, the mutant retina showed a significant increase of artery/vein crossing points, which are rare in wild types (Fig. 3F,J; Fig. 4; Nrp1+/+ 0.4±0.83 versus Nrp1cytoΔ/Δ 2.0±1.36; mean±s.d.; n≥14 each; P<0.001). Similar arteriovenous crossings have previously been identified in the retina of mice with haploinsufficient expression of VEGF in neural progenitors (Haigh et al., 2003), consistent with the idea that NRP1 conveys VEGF signals during vascular development. It is not known whether arteriovenous crossings are restricted to the retina with its unique two-dimensional radial array of arteries and veins, or are also present in other organs of Vegfa or the Nrp1cytoΔ/Δ mutants.
Confocal microscopy of Nrp1cytoΔ/Δ P7 retinas immunolabelled for IB4 and the venous marker NRP2 (Herzog et al., 2001), combined with 3D image rendering, established that the artery was positioned anteriorly to the vein in 13/13 crossings (Fig. 4A-A′). Thus, the vein became `sandwiched' between the artery and neural retina. Immunolabelling for IB4 and NRP1, which is enriched in arteries (Herzog et al., 2001), revealed arteriovenous crossings also in mutants at P21 (Fig. 4B; high magnification of Fig. S1F in the supplementary material). Fluorescein angiography and infrared fundus microscopy identified arteriovenous crossings in the eyes of adult mutants (see Fig. S1G-J in the supplementary material). The presence of arteriovenous crossings at all postnatal stages examined suggests that they form during development and persist into adulthood.
A high frequency of arteriovenous crossings with an anterior position of the artery relative to the vein, combined with sharing of extracellular matrix by the crossed artery and vein, is a risk factor for BRVO (e.g. Weinberg et al., 1993; Zhao et al., 1993; Cahill and Fekrat, 2002). Immunolabelling with the vascular basement membrane/tunica media marker collagen IV (Megens et al., 2007) established that arteries and veins at sites of overlap in Nrp1cytoΔ/Δ mutants were embedded in a contiguous collagen IV-positive extracellular matrix, but that arterial and venous endothelium were segregated by a basement membrane at contact sites (Fig. 4C). The arteriovenous crossings present in the Nrp1cytoΔ/Δ retina are therefore highly similar to those present at sites of BRVO in humans.
NRP2 is the closest relative to NRP1, with the cytoplasmic domain of the NRP2a isoform having a C-terminal SEA motif like NRP1 (Rossignol et al., 2000). Moreover, mice lacking both NRP1 and NRP2 have more severe vascular defects than mice lacking NRP1 alone (Takashima et al., 2002). To address whether the lack of angiogenesis defects in mutants lacking the NRP1 cytoplasmic domain was due to compensation by NRP2, we examined whether NRP2 was upregulated in Nrp1cytoΔ/Δ mutants, but found that this was not the case (see Fig. S2 in the supplementary material). Moreover, loss of the NRP1 cytoplasmic domain on a Nrp2-null background (Giger et al., 2000) did not impair angiogenesis in 3/3 E12.5 hindbrains or 10/10 P7 retinas from double homozygous mutants, and vascular extension and SMC coverage were also unaffected in double mutant retinas (see Fig. S3 in the supplementary material). NRP2 therefore does not compensate for loss of the NRP1 cytoplasmic domain during developmental angiogenesis or artery/vein specification.
Previous in vitro studies reported that the NRP1 cytoplasmic domain modulates VEGFR2 endocytosis in a mechanism that depends on synectin (Wang et al., 2003; Salikhova et al., 2008). These findings were thought to indicate an essential role in VEGF-mediated angiogenesis. However, the comparison of vascular defects in full NRP1 knockouts and Nrp1cytoΔ/Δ mutants implies that the essential angiogenic function of NRP1 involves its extracellular, rather than intracellular, domain. The interaction of the NRP1 cytoplasmic domain with VEGFR2 might therefore be important for endothelial functions other than angiogenesis. Because NRP1 is enriched in arteries and synectin promotes arteriogenesis in ischemic adult tissues, the NRP1 cytoplasmic domain may serve to link synectin and VEGFR2 to promote ERK signalling during adult arteriogenesis (Ren et al., 2010). Future work should therefore address whether Nrp1cytoΔ/Δ mutants have reduced arteriogenic VEGFR2 signalling.
The high frequency of arteriovenous crossings in Nrp1cytoΔ/Δ mutants raises the possibility that these mice could serve as an animal model to elucidate the poorly understood aetiology of BRVO. Thus, the high number of crossings with an anteriorly positioned artery positively increases the risk of developing BRVO in that eye (Weinberg et al., 1990), but it still needs to be determined how these anatomical abnormalities progress to become BRVO lesions. Current hypotheses propose the presence of additional, systemic risk factors such as advanced age, hypertension and cardiovascular disease (Cahill and Fekrat, 2002). For example, it has been hypothesised that an anteriorly placed artery stiffened by atherosclerosis compresses the underlying vein against the neural retina, reducing blood flow downstream of the crossing. By introducing atherosclerosis or other risk factors into Nrp1cytoΔ/Δ mutants and their wild-type littermates, it may be possible to determine their relative significance for lesion formation and devise medical strategies to prevent lesion establishment.
Click here for additional data file (supp_138.19.4185_DEV070037TableS1.pdf)
Click here for additional data file (supp_138.19.4185_DEV070037FigS1.jpg)
Click here for additional data file (supp_138.19.4185_DEV070037FigS2.jpg)
Click here for additional data file (supp_138.19.4185_DEV070037FigS3.jpg)
This study was supported by research grants from the Royal Society (ref. 2005/R2), the UK MRC (ref. G0601093) and the UK British Heart Foundation (BHF, ref. PG/10/86/28622) to C.R., and by a BHF studentship to A.F. (ref. 44626). Deposited in PMC for immediate release.
Competing interests statement
The authors declare no competing financial interests.
Supplementary material for this article is available at http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.070037/-/DC1
We thank Caiying Guo and the staff of the GTTF for their invaluable assistance with gene targeting, and Matthew Golding for critical reading of the manuscript. We are grateful to the staff of the Biological Resources Unit for mouse husbandry, to Peter Munro in the Imaging Facility of the UCL Institute of Ophthalmology for help with confocal microscopy and to Francesca Cordeiro for access to imaging equipment.
|Allport J. R.,Lim Y. C.,Shipley J. M.,Senior R. M.,Shapiro S. D.,Matsuyoshi N.,Vestweber D.,Luscinskas F. W.. (Year: 2002). Neutrophils from MMP-9- or neutrophil elastase-deficient mice show no defect in transendothelial migration under flow in vitro. J. Leukoc. Biol.71, 821-82811994507|
|Angrand P. O.,Daigle N.,van der Hoeven F.,Scholer H. R.,Stewart A. F.. (Year: 1999). Simplified generation of targeting constructs using ET recombination. Nucleic Acids Res.27, e1610446259|
|Cahill M. T.,Fekrat S.. (Year: 2002). Arteriovenous sheathotomy for branch retinal vein occlusion. Ophthalmol. Clin. North Am.15, 417-42312515073|
|Cai H.,Reed R. R.. (Year: 1999). Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J. Neurosci.19, 6519-652710414980|
|Chittenden T. W.,Claes F.,Lanahan A. A.,Autiero M.,Palac R. T.,Tkachenko E. V.,Elfenbein A.,Ruiz de Almodovar C.,Dedkov E.,Tomanek R.,et al. (Year: 2006). Selective regulation of arterial branching morphogenesis by synectin. Dev. Cell10, 783-79516740480|
|De Vries L.,Lou X.,Zhao G.,Zheng B.,Farquhar M. G.. (Year: 1998). GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP. Proc. Natl. Acad. Sci. USA95, 12340-123459770488|
|Fantin A.,Maden C. H.,Ruhrberg C.. (Year: 2009). Neuropilin ligands in vascular and neuronal patterning. Biochem. Soc. Trans.37, 1228-123219909252|
|Fantin A.,Vieira J. M.,Gestri G.,Denti L.,Schwarz Q.,Prykhozhij S.,Peri F.,Wilson S. W.,Ruhrberg C.. (Year: 2010). Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood116, 829-84020404134|
|Fruttiger M.. (Year: 2007). Development of the retinal vasculature. Angiogenesis10, 77-8817322966|
|Fujisawa H.. (Year: 2002). From the discovery of neuropilin to the determination of its adhesion sites. Adv. Exp. Med. Biol.515, 1-1212613539|
|Gao Y.,Li M.,Chen W.,Simons M.. (Year: 2000). Synectin, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J. Cell. Physiol.184, 373-37910911369|
|Gerhardt H.,Ruhrberg C.,Abramsson A.,Fujisawa H.,Shima D.,Betsholtz C.. (Year: 2004). Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev. Dyn.231, 503-50915376331|
|Giger R. J.,Cloutier J. F.,Sahay A.,Prinjha R. K.,Levengood D. V.,Moore S. E.,Pickering S.,Simmons D.,Rastan S.,Walsh F. S.,et al. (Year: 2000). Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron25, 29-4110707970|
|Gluzman-Poltorak Z.,Cohen T.,Herzog Y.,Neufeld G.. (Year: 2000). Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J. Biol. Chem.275, 18040-1804510748121|
|Gluzman-Poltorak Z.,Cohen T.,Shibuya M.,Neufeld G.. (Year: 2001). Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J. Biol. Chem.276, 18688-1869411278319|
|Gu C.,Limberg B. J.,Whitaker G. B.,Perman B.,Leahy D. J.,Rosenbaum J. S.,Ginty D. D.,Kolodkin A. L.. (Year: 2002). Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J. Biol. Chem.277, 18069-1807611886873|
|Haigh J. J.,Morelli P. I.,Gerhardt H.,Haigh K.,Tsien J.,Damert A.,Miquerol L.,Muhlner U.,Klein R.,Ferrara N.,et al. (Year: 2003). Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev. Biol.262, 225-24114550787|
|Herzog Y.,Kalcheim C.,Kahane N.,Reshef R.,Neufeld G.. (Year: 2001). Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev.109, 115-11911677062|
|Jones E. A.,Yuan L.,Breant C.,Watts R. J.,Eichmann A.. (Year: 2008). Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos. Development135, 2479-248818550715|
|Kappas N. C.,Zeng G.,Chappell J. C.,Kearney J. B.,Hazarika S.,Kallianos K. G.,Patterson C.,Annex B. H.,Bautch V. L.. (Year: 2008). The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J. Cell Biol.181, 847-85818504303|
|Kawasaki T.,Kitsukawa T.,Bekku Y.,Matsuda Y.,Sanbo M.,Yagi T.,Fujisawa H.. (Year: 1999). A requirement for neuropilin-1 in embryonic vessel formation. Development126, 4895-490210518505|
|Lanahan A. A.,Hermans K.,Claes F.,Kerley-Hamilton J. S.,Zhuang Z. W.,Giordano F. J.,Carmeliet P.,Simons M.. (Year: 2010). VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev. Cell18, 713-71420434959|
|Megens R. T.,Oude Egbrink M. G.,Cleutjens J. P.,Kuijpers M. J.,Schiffers P. H.,Merkx M.,Slaaf D. W.,van Zandvoort M. A.. (Year: 2007). Imaging collagen in intact viable healthy and atherosclerotic arteries using fluorescently labeled CNA35 and two-photon laser scanning microscopy. Mol. Imaging6, 247-26017711780|
|Nakamura F.,Tanaka M.,Takahashi T.,Kalb R. G.,Strittmatter S. M.. (Year: 1998). Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron21, 1093-11009856464|
|Ozerdem U.,Grako K. A.,Dahlin-Huppe K.,Monosov E.,Stallcup W. B.. (Year: 2001). NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn.222, 218-22711668599|
|Pan Q.,Chathery Y.,Wu Y.,Rathore N.,Tong R. K.,Peale F.,Bagri A.,Tessier-Lavigne M.,Koch A. W.,Watts R. J.. (Year: 2007). Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem.282, 24049-2405617575273|
|Paye J. M.,Phng L. K.,Lanahan A. A.,Gerhard H.,Simons M.. (Year: 2009). Synectin-dependent regulation of arterial maturation. Dev. Dyn.238, 604-61019235722|
|Prahst C.,Heroult M.,Lanahan A. A.,Uziel N.,Kessler O.,Shraga-Heled N.,Simons M.,Neufeld G.,Augustin H. G.. (Year: 2008). Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J. Biol. Chem.283, 25110-2511418628209|
|Ren B.,Deng Y.,Mukhopadhyay A.,Lanahan A. A.,Zhuang Z. W.,Moodie K. L.,Mulligan-Kehoe M. J.,Byzova T. V.,Peterson R. T.,Simons M.. (Year: 2010). ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J. Clin. Invest.120, 1217-122820237411|
|Risau W.. (Year: 1997). Mechanisms of angiogenesis. Nature386, 671-6749109485|
|Rossignol M.,Gagnon M. L.,Klagsbrun M.. (Year: 2000). Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics70, 211-22211112349|
|Ruhrberg C.. (Year: 2003). Growing and shaping the vascular tree: multiple roles for VEGF. BioEssays25, 1052-106014579246|
|Ruhrberg C.,Gerhardt H.,Golding M.,Watson R.,Ioannidou S.,Fujisawa H.,Betsholtz C.,Shima D. T.. (Year: 2002). Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev.16, 2684-269812381667|
|Salikhova A.,Wang L.,Lanahan A. A.,Liu M.,Simons M.,Leenders W. P.,Mukhopadhyay D.,Horowitz A.. (Year: 2008). Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ. Res.103, e71-e7918723443|
|Schwarz Q.,Ruhrberg C.. (Year: 2010). Neuropilin, you gotta let me know: should I stay or should I go?Cell Adh. Migr.4, 61-6620026901|
|Schwarz Q.,Gu C.,Fujisawa H.,Sabelko K.,Gertsenstein M.,Nagy A.,Taniguchi M.,Kolodkin A. L.,Ginty D. D.,Shima D. T.,et al. (Year: 2004). Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev.18, 2822-283415545635|
|Schwarz Q.,Vieira J. M.,Howard B.,Eickholt B. J.,Ruhrberg C.. (Year: 2008). Neuropilin 1 and 2 control cranial gangliogenesis and axon guidance through neural crest cells. Development135, 1605-161318356247|
|Shibuya M.. (Year: 2006). Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol.39, 469-47817002866|
|Soker S.,Takashima S.,Miao H. Q.,Neufeld G.,Klagsbrun M.. (Year: 1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell92, 735-7459529250|
|Soker S.,Miao H. Q.,Nomi M.,Takashima S.,Klagsbrun M.. (Year: 2002). VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem.85, 357-36811948691|
|Takashima S.,Kitakaze M.,Asakura M.,Asanuma H.,Sanada S.,Tashiro F.,Niwa H.,Miyazaki J.,Hirota S.,Kitamura Y.,et al. (Year: 2002). Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc. Natl. Acad. Sci. USA99, 3657-366211891274|
|Valdembri D.,Caswell P. T.,Anderson K. I.,Schwarz J. P.,Konig I.,Astanina E.,Caccavari F.,Norman J. C.,Humphries M. J.,Bussolino F.,et al. (Year: 2009). Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol.7, e2519175293|
|Vieira J. M.,Schwarz Q.,Ruhrberg C.. (Year: 2007). Selective requirements for NRP1 ligands during neurovascular patterning. Development134, 1833-184317428830|
|Wang L.,Zeng H.,Wang P.,Soker S.,Mukhopadhyay D.. (Year: 2003). Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J. Biol. Chem.278, 48848-4886014514674|
|Wang L.,Mukhopadhyay D.,Xu X.. (Year: 2006). C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J.20, 1513-151516754745|
|Weinberg D.,Dodwell D. G.,Fern S. A.. (Year: 1990). Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am. J. Ophthalmol.109, 298-3022309862|
|Whitaker G. B.,Limberg B. J.,Rosenbaum J. S.. (Year: 2001). Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J. Biol. Chem.276, 25520-2553111333271|
|Yuan L.,Moyon D.,Pardanaud L.,Breant C.,Karkkainen M. J.,Alitalo K.,Eichmann A.. (Year: 2002). Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development129, 4797-480612361971|
|Zhao J.,Sastry S. M.,Sperduto R. D.,Chew E. Y.,Remaley N. A.. (Year: 1993). Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology100, 423-4288460014|
Keywords: Neuropilin, Angiogenesis, Artery, Vein, VEGF.
Previous Document: HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells.
Next Document: Notch pathway activation can replace the requirement for Wnt4 and Wnt9b in mesenchymal-to-epithelial...